"Priority" Review Slow Down: The Prasugrel Delay
This article was originally published in RPM Report
Executive Summary
FDA is looking at a February advisory committee for the Lilly/Daiichi anti-clotting drug. That would put the review of the "priority" application at 14 months and counting. What does prasugrel mean for the priority review process?